PP09. CYTOGENETIC ANALYSIS OF MISCARRIAGES IN PREGNANCY EARLY STAGES
JASMINA DURKOVIC1, Luka Andjelic2, Miladin Knezevic2 Medical centre Subotica, 1. Department of Genetics; 2. Gynecology and obstetrics ward, Subotica, Serbia and Montenegro e-mail: megalab@ptt.yu
*Corresponding Author:
page: 52

Abstract

This paper deals with investigation of how miscarriages in early pregnancy and chromosomopathy are related.

The frequency of chromosome aberrations occurrence in miscarriages in early pregnancy has been demonstrated. The analysis of 304 chorions and fetal tissues was made at the Medical centre in Subotica in the period 2001. 2005.

Cytogenetic analysis was made in chorion villi in the embryo tissue, most often in lungs because of the high mitotic index. The tissue sample was directly prepared without addition of any mitogens or incubation.

A total of 76 chromosome aberration was discovered which makes 25% of all miscarriages.

The most frequent chromosomopathy was a polyploidy (8,5%) and trisomy 16 (5,6%).

A significant increase was noticed concerning the presence of chromosomopathy per ages, 18% of cases in 2001, 21% in 2002, 23% in 2003, 26% in 2004, 29% in 2005.

The importance of cytogenetic analysis of miscarriages is in indicating the karyotyping of parents in which chromosomopathy of fetus has been found and also in discovering the host of balanced structural chromosome aberrations, in which a prenatal karyotyping in the subsequent pregnancy is necessary. Cytogenetic analysis is most often performed following a number of miscarriages of unknown etiology. In our sample, analysis was made in a non-selected population of pathologic pregnancies. Chromosome aberrations were discovered after the first miscarriage. Analysis of each miscarriage shows deviation of conception at the chromosome level even in first pregnancy and induces karyotyping of spouses.

Monitoring the presence of chromosome aberrations in miscarried fetuses is an indication of the general population risk which defines the guidelines for the preventive measures to be taken.




Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006